Abstract:The epidermal growth factor receptor (EGFR) serves as an attractive target for cancer molecular imaging and therapy. Our previous positron emission tomography (PET) studies showed that the EGFR-targeting affibody molecules Cu-64-DOTA-ZEGFR:1907 and F-18-FBEM-ZEGFR:1907 can discriminate between high and low EGFR-expression tumors and have the potential for patient selection for EGFR-targeted therapy. Compared with Cu-64, F-18 may improve imaging of EGFR-expression and is more suitable for clinical application, but the labeling reaction of F-18-FBEM-ZEGFR:1907 requires a long synthesis time. The aim of the present study is to develop a new generation of F-18 labeled affibody probes ((AlF)-F-18-NOTA-ZEGFR:1907 and F-18-CBT-ZEGFR:1907) and to determine whether they are suitable agents for imaging of EGFR expression. The first approach consisted of conjugating ZEGFR:1907 with NOTA and radiolabeling with (AlF)-F-18 to produce (AlF)-F-18-NOTA-ZEGFR:1907. In a second approach the prosthetic group F-18-labeled-2-cyanobenzothiazole (F-18-CBT) was conjugated to Cys-ZEGFR:1907 to produce F-18-CBT-ZEGFR:1907. Binding affinity and specificity of (AlF)-F-18-NOTA-ZEGFR:1907 and F-18-CBT-ZEGFR:1907 to EGFR were evaluated using A431 cells. Biodistribution and PET studies were conducted on mice bearing A431 xenografts after injection of (AlF)-F-18-NOTA-ZEGFR:1907 or F-18-CBT-ZEGFR:1907 with or without coinjection of unlabeled affibody proteins. The radiosyntheses of (AlF)-F-18-NOTA-ZEGFR:1907 and F-18-CBT-ZEGFR:1907 were completed successfully within 40 and 120 min with a decay-corrected yield of 15% and 41% using a 2-step, 1-pot reaction and 2-step, 2-pot reaction, respectively. Both probes bound to EGFR with low nanomolar affinity in A431 cells. Although F-18-CBT-ZEGFR:1907 showed instability in vivo, biodistribution studies revealed rapid and high tumor accumulation and quick clearance from normal tissues except the bones. In contrast, (AlF)-F-18-NOTA-ZEGFR:1907 demonstrated high in vitro and in vivo stability, high tumor uptake, and relative low uptake in most of the normal organs except the liver and kidneys at 3 h after injection. The specificity of both probes for A431 tumors was confirmed by their lower uptake on coinjection of unlabeled affibody. PET studies showed that (AlF)-F-18-NOTA-ZEGFR:1907 and F-18-CBT-ZEGFR:1907 could clearly identify EGFR positive tumors with good contrast. Two strategies for F-18-labeling of affibody molecules were successfully developed as two model platforms using NOTA or CBT coupling to affibody molecules that contain an N-terminal cysteine. (AlF)-F-18-NOTA-ZEGFR:1907 and F-18-CBT-ZEGFR:1907 can be reliably obtained in a relatively short time. Biodistribution and PET studies demonstrated that (AlF)-F-18-NOTA-ZEGFR:1907 is a promising PET probe for imaging EGFR expression in living mice.

Pharmacokinetic analysis of 6-O-[18F]FEE for PET imaging of EGFR mutation

PET of EGFR Expression with an 18F-Labeled Affibody Molecule

Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Positive Tumor with a 64cu Labeled Affibody Protein

Comparison of two site-specifically (18)F-labeled affibodies for PET imaging of EGFR positive tumors.

Synthesis and evaluation of 64 Cu-radiolabeled NOTA-cetuximab ( 64 Cu-NOTA-C225) for immuno-PET imaging of EGFR expression.

Synthesis and preclinical evaluation of [11C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptor

Affibody Molecule for Positron Emission Tomography Imaging of Human Epidermal Growth Factor Receptor: Validation in Mouse Models and Human Cancer Tissues

A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice

Radiosynthesis and Evaluation of 4-(6-[18f]fluoro-4-(5-isopropoxy-1h-indazol-3-yl)pyridin-2-yl)morpholine As a Novel Radiotracer Candidate Targeting Leucine-Rich Repeat Kinase 2.

Metabolism of Epidermal Growth Factor Receptor Targeting Probe [11C]PD153035: Impact on Biodistribution and Tumor Uptake in Rats

18F-labeled FGFR1 peptide: a new PET probe for subtype FGFR1 receptor imaging

Further Characterization of the Epidermal Growth Factor Receptor Ligand 11C-PD153035

Use of Fdg-Pet for Early Response Assessment of Novel Egfr Kinase Inhibitors in Mouse Models of Lung Cancer

Synthesis and Biological Evaluation of Novel F-18 Labeled Pyrazolo[1,5-A]pyrimidine Derivatives: Potential PET Imaging Agents for Tumor Detection.

Evaluation of (2S,4S)-4-[18F]FEBGln as a Positron Emission Tomography Tracer for Tumor Imaging

Synthesis and Biological Evaluation of 7-(2-chlorophenylamino)-5-((2- [18F]fluoro-Ethyoxy)methyl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile As PET Tumor Imaging Agent

Molecular imaging of epidermal growth factor receptor in glioma-bearing rats]

In Vivo PET Imaging of EGFR Expression: an Overview of Radiolabeled EGFR TKIs

Facile fully automated radiosynthesis and quality control of O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET) for human brain tumor imaging

Preclinical PET Imaging of EGFR Levels: Pairing a Targeting with a Non-Targeting Sel-tagged Affibody-based Tracer to Estimate the Specific Uptake

Synthesis of 2-R 1 -2-(4-(2-fluoroethoxy)benzamido)acetate As Potential PET Imaging Agents